Behcet Disease - Pipeline Review, H1 2020

April 2020 | 65 pages | ID: BF054E1C19FEN
Global Markets Direct

Abstracts

Behcet Disease - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

'Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Beh?et, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals(sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.'

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Behcet Disease - Overview
Behcet Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Behcet Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Behcet Disease - Companies Involved in Therapeutics Development
Amgen Inc
GlaxoSmithKline Plc
Iltoo Pharma
InSight Biopharmaceuticals Ltd
Novartis AG
Pharmapraxis
R Pharm
Silk Road Therapeutics
Behcet Disease - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1070806 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentoxifylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Behcet Disease - Dormant Projects
Behcet Disease - Discontinued Products
Behcet Disease - Product Development Milestones
Featured News & Press Releases
Feb 27, 2020: CHMP recommended extensions of indication for Otezla
Jul 19, 2019: FDA approves OTEZLA (apremilast) for the treatment of oral ulcers associatd with Behcet’s Disease
Feb 17, 2018: OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet
Apr 15, 2015: Phase II Data for Apremilast in Beh?et's Disease Published in The New England Journal of Medicine
Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Beh?et’s Disease At EULAR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Behcet Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Behcet Disease - Pipeline by Amgen Inc, H1 2020
Behcet Disease - Pipeline by GlaxoSmithKline Plc, H1 2020
Behcet Disease - Pipeline by Iltoo Pharma, H1 2020
Behcet Disease - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
Behcet Disease - Pipeline by Novartis AG, H1 2020
Behcet Disease - Pipeline by Pharmapraxis, H1 2020
Behcet Disease - Pipeline by R Pharm, H1 2020
Behcet Disease - Pipeline by Silk Road Therapeutics, H1 2020
Behcet Disease - Dormant Projects, H1 2020
Behcet Disease - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Behcet Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Amgen Inc
GlaxoSmithKline Plc
Iltoo Pharma
InSight Biopharmaceuticals Ltd
Novartis AG
Pharmapraxis
R Pharm
Silk Road Therapeutics